Comparative ocular bioavailability and efficacy of topical levofloxacin and ofloxacin in rabbits

Journal of Toxicology - Cutaneous and Ocular Toxicology

Volumn 23, Issue 2, 2004, Pages 83-90

  Bezwada, Padma ^a   Clark, Leslie ^a   Adams, Steven ^b   O'Brien, Terrance ^c   Schultz, Gregory ^d  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Keratitis; Levofloxacin; Ocular bioavailability; Ofloxacin; Pseudomonas; Quinolone; Rabbits

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; EXPERIMENTAL INFECTION; EYE; FEMALE; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCULAR BIOAVAILABILITY; PSEUDOMONAS; RABBIT;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA; ORYCTOLAGUS CUNICULUS; POSIBACTERIA; PSEUDOMONAS;

EID: 2542537511     PISSN: 07313829     EISSN: None     Source Type: Journal    
DOI: 10.1081/CUS-120029763     Document Type: Article

References (12)

1. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47:677-700.
2. max as a pharmacokinetic parameter of ophthalmic solution. J Eye 1995; 12:783-786.
3. Clark L, Bezwada P, Hosoi K, Ikuse T, Adams S, Schultz GS, O'Brien T. Evaluation of ocular toxicity of topial levofloxacin in rabbit and primate models. Cutan Ocul Toxicol 2004; 23(1):1-18.
4. Brightwell J, Eiferman RA, Valenzuela P, Barr PJ, Merryweather JP, Schultz GS. Acceleration of corneal wound healing in primates by human epidermal growth factor. Investig Ophthalmol Vis Sci 1885; 26:105-110.
5. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses and toxicities in humans. Antimicrob Agents Chemother 1985; 28:716-721.
6. Shen LL, Pemet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc Natl Acad Sci 1985; 82:307-311.
7. Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986; 18(suppl D):21-29.
8. Tanaka KI, Iwamoto M, Maesaki S, Koga H, Kohno S, Hara K, Sugawara K, Kaku M, Kusano S, Sakito O. Basic and clinical studies on levofloxacin in the treatment of respiratory infections. Jpn J Antibiot 1992; 45:548-555.
9. Brighty KE, Gootz TD. Chemistry and mechanism of action of the quinolone antibacterials. In: The Quinolones. 3rd ed. San Diego: Academic Press, CA, 2000: 33-97.
10. Bui DP, Dang SB, Hwang DG. Effect of ciprofloxacin concentration on mutational resistance rates in S. aureus. Investig Ophthalmol Vis Sci 1995; 36:4876.
11. Almer LS, Shortridge VD, Nilius AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225-232.
12. Physicians Desk Reference. 57th ed. Montvale: Thompson Health Care, NJ, 2003.